Apoptosis induced in HepG2 cells by the synthetic cannabinoid WIN: Involvement of the transcription factor PPARγ

Biochimie

Volumn 91, Issue 4, 2009, Pages 457-465

  Giuliano, Michela ^a   Pellerito, Ornella ^a   Portanova, Patrizia ^a   Calvaruso, Giuseppe ^a   Santulli, Andrea ^a   De Blasio, Anna ^a   Vento, Renza ^a   Tesoriere, Giovanni ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Apoptosis; Cannabinoids; Hepatoma cells; PPAR

Indexed keywords

ANILIDES; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BENZAMIDES; BENZOXAZINES; CANNABINOIDS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL SURVIVAL; HUMANS; LIVER NEOPLASMS; MEMBRANE MICRODOMAINS; MORPHOLINES; NAPHTHALENES; PPAR GAMMA; PROTEIN KINASES; PYRIDINES; RECEPTOR, CANNABINOID, CB2; SIGNAL TRANSDUCTION;

EID: 62649170623     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2008.11.003     Document Type: Article

References (40)

1. Watson S.J., Benson Jr. J.A., and Joy J.E. Marijuana and medicine: assessing the science base: a summary of the 1999 Institute of Medicine report. Arch. Gen. Psychiatry 57 (2000) 547-552
2. Pertwee R.G. Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and development. Expert. Opin. Invest. Drugs 9 (2000) 1553-1571
3. Porter A.C., and Felder C.C. The endocannabinoid nervous system: unique opportunities for therapeutic intervention. Pharmacol. Ther 90 (2001) 45-60
4. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., and Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258 (1992) 1946-1949
5. van der Stelt M., and Di Marzo V. Cannabinoid receptors and their role in neuroprotection. Neuromol. Med 7 (2005) 37-50
6. Dainese E., Oddi S., Bari M., and Maccarrone M. Modulation of the endocannabinoid system by lipid rafts. Curr. Med. Chem. 14 (2007) 2702-2715
7. Howlett A.C., Barth F., Bonner T.I., Cabral G., Casellas P., Devane W.A., Felder C.C., Herkenham M., Mackie K., Martin B.R., Mechoulam R., and Pertwee R.G. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. 54 (2002) 161-202
8. Herkenham M., Lynn A.B., Johnson M.R., Melvin L.S., de Costa B.R., and Rice K.C. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J. Neurosci 11 (1991) 563-583
9. Guzman M. Cannabinoids: potential anticancer agents. Nat Rev Cancer 3 (2003) 745-755
10. Sarfaraz S., Afaq F., Adhami V.M., and Mukhtar H. Cannabinoid receptor as a novel target for the treatment of prostate cancer. Cancer Res. 65 (2005) 1635-1641
11. Sarker K.P., Biswas K.K., Yamakuchi M., Lee K.Y., Hahiguchi T., Kracht M., Kitajima I., and Maruyama I. ASK1-p38 MAPK/JNK signaling cascade mediates anandamide-induced PC12 cell death. J Neurochem 85 (2003) 50-61
12. Velasco G., Galve-Roperh I., Sánchez C., Blázquez C., and Guzmán M. Hypothesis: cannabinoid therapy for the treatment of gliomas?. Neuropharmacol 47 (2004) 315-323
13. Sarfaraz S., Afaq F., Adhami V.M., Malik A., and Mukhtar H. Cannabinoid receptor agonist-induced apoptosis of human prostate cancer cells LNCaP proceeds through sustained activation of ERK1/2 leading to G1 cell cycle arrest. J. Biol. Chem. 281 (2006) 39480-39491
14. Gustafsson K., Christensson B., Sander B., and Flygare J. Cannabinoid receptor-mediated apoptosis induced by R(+)-methanandamide and Win55,212-2 is associated with ceramide accumulation and p38 activation in mantle cell lymphoma. Mol. Pharmacol 70 (2006) 1612-1620
15. Velasco G., Galve-Roperh I., Sánchez C., Blázquez C., Haro A., and Guzmán M. Cannabinoids and ceramide: two lipids acting hand-by-hand. Life Sci. 77 (2005) 1723-1731
16. Sánchez C., Galve-Roperh I., Rueda D., and Guzmán M. Involvement of sphingomyelin hydrolysis and the mitogen-activated protein kinase cascade in the Delta9-tetrahydrocannabinol-induced stimulation of glucose metabolism in primary astrocytes. Mol. Pharmacol 54 (1998) 834-843
17. Galve-Roperh I., Sánchez C., Cortés M.L., Gómez del Pulgar T., Izquierdo M., and Guzmán M. Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nature Med 6 (2000) 313-319
18. Demuth D.G., and Molleman A. Cannabinoid signalling. Life Sci. 78 (2006) 549-563
19. Pozzoli G., Tringali G., Vairano M., D'Amico M., Navarra P., and Martire M. Cannabinoid agonist WIN55,212-2 induces apoptosis in cerebellar granule cells via activation of the CB1 receptor and downregulation of bcl-xL gene expression. J. Neurosci. Res. 83 (2006) 1058-1065
20. O'Sullivan S.E. Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. Br. J. Pharmacol 152 (2007) 576-582
21. Lazar M.A. PPAR gamma 10 years later. Biochimie 87 (2005) 9-13
22. Krishnan A., Nair S.A., and Pillai M.R. Biology of PPAR gamma in cancer: a critical review on existing lacunae. Curr. Mol. Med 7 (2007) 532-540
23. Bouaboula M., Hilairet S., Marchand J., Fajas L., Le Fur G., and Casellas P. Anandamide induced PPARgamma transcriptional activation and 3T3-L1 preadipocyte differentiation. Eur. J. Pharmacol 517 (2005) 174-181
24. Burstein S. PPAR-gamma: a nuclear receptor with affinity for cannabinoids. Life Sci. 77 (2005) 1674-1684
25. Ambrosio A.L., Dias S.M., Polikarpov I., Zurier R.B., Burstein S.H., and Garratt R.C. Ajulemic acid, a synthetic nonpsychoactive cannabinoid acid, bound to the ligand binding domain of the human peroxisome proliferator-activated receptor gamma. J. Biol. Chem. 282 (2007) 18625-18633
26. Pagano C., Pilon C., Calcagno A., Urbanet R., Rossato M., Milan G., Bianchi K., Rizzuto R., Bernante P., Federspil G., and Vettor R. The endogenous cannabinoid system stimulates glucose uptake in human fat cells via phosphatidylinositol 3-kinase and calcium-dependent mechanisms. J. Clin. Endocrinol. Metab 92 (2007) 4810-4819
27. Emanuele S., D'Anneo A., Bellavia G., Vassallo B., Lauricella M., De Blasio A., Vento R., and Tesoriere G. Sodium butyrate induces apoptosis in human hepatoma cells by a mitochondria/ caspase pathway, associated with degradation of beta-catenin, pRb and Bcl-XL. Eur. J. Cancer 40 (2004) 1441-1452
28. Lauricella M., Emanuele S., D'Anneo A., Calvaruso G., Vassallo B., Carlisi D., Portanova P., Vento R., and Tesoriere G. JNK and AP-1 mediate apoptosis induced by bortezomib in HepG2 cells via FasL/caspase-8 and mitochondria-dependent pathways. Apoptosis 11 (2006) 607-625
29. Duffy M.J., O'Donovan N., Brennan D.J., Gallagher W.M., and Ryan B.M. Survivin: a promising tumor biomarker. Cancer Lett. 249 (2007) 49-60
30. Calvaruso G., Giuliano M., Portanova P., Pellerito O., Vento R., and Tesoriere G. Hsp72 controls bortezomib-induced HepG2 cell death via interaction with pro-apoptotic factors. Oncol. Rep 18 (2007) 447-450
31. Tokunaga E., Oki E., Egashira A., Sadanaga N., Morita M., Kakeji Y., and Maehara Y. Deregulation of the AKT pathway in human cancer. Curr. Cancer Drug Targets 8 (2008) 27-36
32. Kuo C.T., Hsu M.J., Chen B.C., Chen C.C., Teng C.M., Pan S.L., and Lin C.H. Denbinobin induces apoptosis in human lung adenocarcinoma cells via AKT inactivation, Bad activation, and mitochondrial dysfunction. Toxicol. Lett. 177 (2008) 48-58
33. Harikumar K.B., and Aggarwal B.B. Resveratrol: a multitargeted agent for age-associated chronic diseases. Cell Cycle 7 (2008) 1020-1035
34. Rimmerman N., Hughes H.V., Bradshaw H.B., Pazos M.X., Mackie K., Prieto A.L., and Walker J.M. Compartmentalization of endocannabinoids into lipid rafts in a dorsal root ganglion cell line. Br. J. Pharmacol 153 (2008) 380-389
35. Reddy R.M., Yeow W.S., Chua A., Nguyen D.M., Baras A., Ziauddin M.F., Shamimi-Noori S.M., Maxhimer J.B., Schrump D.S., and Nguyen D.M. Rapid and profound potentiation of Apo2L/TRAIL-mediated cytotoxicity and apoptosis in thoracic cancer cells by the histone deacetylase inhibitor Trichostatin A: the essential role of the mitochondria-mediated caspase activation cascade. Apoptosis 12 (2007) 55-71
36. Accorsi-Mendonça D., Almado C.E., Dagostin A.L., Machado B.H., and Leão R.M. Inhibition of spontaneous neurotransmission in the nucleus of solitary tract of the rat by the cannabinoid agonist WIN 55212-2 is not via CB1 or CB2 receptors. Brain Res. 1200 (2008) 1-9 C
37. Kim K.Y., Kim S.S., and Cheon H.G. Differential anti-proliferative actions of peroxisome proliferator-activated receptor-gamma agonists in MCF-7 breast cancer cells. Biochem. Pharmacol 72 (2006) 530-540
38. Schaefer K.L., Takahashi H., Morales V.M., Harris G., Barton S., Osawa E., Nakajima A., and Saubermann L.J. PPARgamma inhibitors reduce tubulin protein levels by a PPARgamma, PPARdelta and proteasome-independent mechanism, resulting in cell cycle arrest, apoptosis and reduced metastasis of colorectal carcinoma cells. Int. J. Cancer 120 (2007) 702-713
39. Diradourian C., Girard J., and Pégorier J.P. Phosphorylation of PPARs: from molecular characterization to physiological relevance. Biochimie 87 (2005) 33-38
40. Maggiora M., Bologna M., Cerù M.P., Possati L., Angelucci A., Cimini A., Miglietta A., Bozzo F., Margiotta C., Muzio G., and Canuto R.A. An overview of the effect of linoleic and conjugated-linoleic acids on the growth of several human tumor cell lines. Int. J. Cancer 112 (2004) 909-919